INKT News and Press, MiNK Therapeutics Inc. From 11/12/21

No evidence of neurotoxicity or cytokine release syndrome Early signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma iNKTs demonstrated potent tumor killing in solid tumor models NEW YORK, Nov. 12, 2021 (G...

Several Wall Street analysts have initiated their coverage on MiNK Therapeutics (INKT +6.1%) with Buy equivalent ratings driving the stock higher for the second consecutive session. B. Riley Securities' analyst Kalpit Patel argues that the company’s invariant natural killer T (iNKT) ce...

Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy Agenus will commence Phase 2/3 trials of AGEN1181 and balstilim...

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated dis...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The rush of earnings reports slows down just a bit in the week ahead, but still sees big names like Disney (NYSE:DIS), U...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated dis...